💨 Abstract

Larimar Therapeutics reported a Q2 loss of $26.2 million, or 41 cents per share, which was better than Wall Street’s expected 47 cents per share loss. The company's results exceeded analysts' expectations according to Zacks Investment Research.

Courtesy: WTOP Staff